Group 1 - The company Jiangnan Buyi (03306) announced the issuance of new shares totaling 14.535 million shares on January 30, 2026, according to a placement agreement dated January 23, 2026 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) 03306 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的結存(註1) 2025年12月31日 | | 518,750,000 | | | 0 | | | 518,750,000 | | 1). 配售/認購 - 涉及新股 | | 14 ...

Core Viewpoint - Jiangnan Buyi (03306) has successfully completed a placement of shares as per the terms of the placement agreement dated January 23, 2026, with no major shareholders being created as a result of this placement [1] Group 1: Placement Details - A total of 14.535 million shares were successfully placed at a price of HKD 18.78 per share [1] - This placement represents approximately 2.80% of the total issued shares as of the placement agreement date [1] - Following the completion of the placement, the enlarged total issued shares will reflect approximately 2.73% [1]

Group 1 - The placement agreement dated January 23, 2026, has been fulfilled, and the placement has been completed on January 30, 2026, with no major shareholders emerging from the placement [1] - A total of 14.535 million shares were successfully placed at a price of HKD 18.78 per share, representing approximately 2.80% of the total issued shares as of the placement agreement date and about 2.73% of the enlarged total issued shares post-placement [1] - The total proceeds from the placement amount to approximately HKD 272.97 million, with a net amount of approximately HKD 269.99 million [1] Group 2 - The company plans to utilize the net proceeds as follows: approximately 40% or HKD 108.00 million for strengthening brand business development, about 50% or HKD 135.00 million for R&D investment to enhance overall market competitiveness, and approximately 10% or HKD 27.00 million for general and corporate purposes [1] - The company estimates that the net proceeds from the placement will be fully utilized by December 2026 [1]

Core Viewpoint - Jiangnan Buyi (03306) has successfully completed a placement of 14.535 million shares at a price of HKD 18.78 per share, with no major shareholders emerging from the placement [1] Group 1: Placement Details - The placement agreement conditions were fulfilled, and the placement was completed on January 30, 2026 [1] - A total of 14.535 million shares were placed, representing approximately 2.80% of the total shares issued as of the placement agreement date [1] - Following the completion of the placement, the newly issued shares represent about 2.73% of the enlarged total shares [1]

本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並不構成在美國購買或認購證券的任何要約或招攬或其一部分。本公告所述 證券並未且將不會根據一九三三年美國證券法（「美國證券法」）進行登記，亦不會在 美國提呈發售或出售，除非根據美國證券法作出登記或獲豁免或為毋須根據美國證 券法作出登記之交易。本公司無意根據美國證券法登記本公告內所指之任何證券， 或在美國進行證券之公開發售。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任 何其他司法權區內刊發或派發。 （於開曼群島註冊成立的有限公司） JNBY Design Limited （股份代號：3306） 江南布衣有限公司 完成根據一般授權 配售新股份 整體協調人、配售代理及資本市場中介人 完成配售新股份 董事會欣然宣佈，日期為二零二六年一月二十三日的配售協議（「配售協議」）所載之 所有條件已獲達成且配售事項已於二 ...

Group 1 - CMB International maintains a "Buy" rating for Anta Sports with a target price of HKD 108.70, noting a low single-digit decline in Q4 revenue for the Anta brand, while FILA and other brands show resilience with a growth of 35%-40% [1] - CMB International also maintains a "Buy" rating for China Resources Beverage with a target price of HKD 11.87, indicating that 2025 will be a year of pressure release, with stable market share in packaged water and potential improvements in sales incentives [1] Group 2 - CMB International maintains a "Buy" rating for Hutchison China MediTech, highlighting the significant superiority of Savolitinib combination therapy over chemotherapy in MET amplified NSCLC, with global sales peak potential exceeding USD 1.8 billion [2] - CMB International maintains a "Buy" rating for China Resources Power with a target price of HKD 21.05, projecting a 6.7% increase in core profit for 2025, with a 9.8% decrease in thermal coal fuel costs partially offsetting coal price rebounds [3] Group 3 - CITIC Securities maintains a "Buy" rating for Geek+, setting a target price of HKD 53.00, with a significant upward revision of order growth from 30% to 40% for 2026, and successful penetration into North American key accounts [4] - CITIC Securities maintains a "Buy" rating for Jiangnan Buyi, noting excellent performance in FY1H26 and a fundraising of HKD 270 million to enhance brand development, with expected high single-digit to double-digit growth in revenue and profit [5] Group 4 - CITIC Securities maintains a "Buy" rating for Xaircraft with a target price of HKD 87.00, emphasizing its leading position in general aviation and private aviation, with current valuations not reflecting its brand potential and scarcity [6] - CITIC Jiantou maintains a "Buy" rating for Xtep International, indicating flat revenue for the main brand in Q4 2025, with bright performance in running categories and successful adjustments in e-commerce [7][8]

Group 1 - The top short-selling ratios are led by AIA Group (81299) and JD Health (86618) at 100.00%, followed by Baidu Group (89888) at 95.46% [1][2] - The highest short-selling amounts are recorded for Pop Mart (09992) at 1.3 billion, Alibaba (09988) at 1.26 billion, and Xiaomi Group (01810) at 1.064 billion [1][2] - The highest deviation values are for Baidu Group (89888) at 62.11%, Shenzhen Expressway (00548) at 37.02%, and SenseTime (80020) at 34.65% [1][2] Group 2 - The top ten short-selling ratios include AIA Group (81299) at 100.00%, JD Health (86618) at 100.00%, and Baidu Group (89888) at 95.46% [2] - The top ten short-selling amounts show Pop Mart (09992) leading with 1.3 billion, followed by Alibaba (09988) with 1.26 billion, and Xiaomi Group (01810) with 1.064 billion [2] - The top ten deviation values highlight Baidu Group (89888) at 62.11%, Shenzhen Expressway (00548) at 37.02%, and SenseTime (80020) at 34.65% [2]

Core Viewpoint - Jiangnan Buyi (03306) experienced a decline of over 6%, currently down 6.69% at HKD 19.26, with a trading volume of HKD 94.915 million [1] Group 1: Share Placement Details - Jiangnan Buyi announced a placement of 14.535 million shares at a price of HKD 18.78 per share [1] - The number of shares placed represents approximately 2.73% of the total issued shares after the completion of the placement [1] - The placement price reflects a discount of about 9.01% compared to the closing price on January 22 [1] Group 2: Use of Proceeds - The total expected proceeds from the placement are approximately HKD 273 million, with net proceeds estimated at around HKD 270 million [1] - The net proceeds will be used to strengthen brand business development, invest in research and development to enhance overall market competitiveness, and for general corporate purposes [1]

Group 1 - Sanhua Intelligent Control (02050) saw a decline of over 3.4% after announcing a share reduction plan involving the actual controller and several directors, with a total of up to approximately 10.2 million A-shares to be sold between February 24, 2026, and May 23, 2026 [1] - Tuo Yun Biotechnology (01332) experienced a significant drop of over 60%, nearly erasing gains since October 2022, following stock movements involving major shareholders [1] - Zhongwei New Materials (02579) increased by over 5% as the company announced securing 5-6 billion wet tons of nickel ore resources and establishing four nickel raw material industrial bases in Indonesia [1] Group 2 - InnoCare Pharma (03696) rose over 6%, reaching a new high of 62.9 HKD, after receiving FDA approval for its oral NLRP3 inhibitor ISM8969 for Parkinson's disease treatment [2] - Solar stocks surged, with Kaisa New Energy (01108) up 17.85% and other companies like Fuyao Glass (06865) and Xinyi Solar (00968) also showing significant gains, driven by a report indicating a new phase in commercial space deployment [2] - Jiangnan Buyi (03306) fell nearly 7% after announcing a placement of 14.535 million shares at a discount to the market price [2] Group 3 - Lithium stocks rose, with Ganfeng Lithium (01772) up 5.22% and Tianqi Lithium (09696) up 2.88%, following a report of a significant increase in lithium carbonate contract prices [3] - Rongchang Bio (09995) increased nearly 2% after UBS expressed a positive outlook on its collaboration with AbbVie, which includes substantial milestone payments [4] - DCH Holdings (00179) fell nearly 7% as it reported a slight decline in revenue for the nine months ending December 31, 2025 [4] Group 4 - Gold stocks rebounded, with Chifeng Jilong Gold Mining (06693) up 6.99% and others also showing gains, as spot gold prices reached a new high of over $4,960 per ounce [4] - Bitgo Holdings (BTGO.US) debuted on the US stock market, rising 2.72% as a leading cryptocurrency custody provider [5] - Rare earth stocks surged, with USA Rare Earth (USAR.US) up 17.49% after announcing partnerships to advance its Round Top project [5] Group 5 - The Nasdaq Golden Dragon China Index opened up 1.6%, with major Chinese stocks like Li Auto (LI.US) and Alibaba (BABA.US) showing gains, supported by comments from the People's Bank of China regarding potential monetary easing [6] - Abbott (ABT.US) fell 10.04% after reporting lower-than-expected sales for Q4 2025, despite a year-over-year increase in adjusted EPS [7] - Alibaba (BABA.US) rose 5.05% as it plans to list its semiconductor division, benefiting from investor interest in competing with Nvidia [7]